The limited data regarding treatment of inflammatory bowel disease (IBD) with anti-tumor necrosis factor antibodies in older patients suggest equal efficacy but higher morbidity and mortality compared to younger patients. This retrospective case control study aims to clarify the efficacy and safety of infliximab (IFX) in older IBD patients.
Recommended CitationLindenmeyer, MD, Christina Cress; Moleski, MD, Stephanie M.; Whitsett, MEd., Maureen P.; and Kozuch, MD, Patricia L., "Efficacy and Safety of Infliximab in Older Inflammatory Bowel Disease Patients" (2013). Division of Gastroenterology and Hepatology Faculty Papers. Paper 21.